Two Pfizer doses give 95 per cent protection against Covid-19 infection, illness and death: first nationwide study
Two doses of a Covid-19 vaccine developed by Pfizer and BioNTech can provide more than 95 per cent protection against infection, severe illness and death, according to the first nation-wide data from Israel.
A single dose of the jab, meanwhile, is associated with 58 per cent protection against infection, 76 per cent against hospital admission, and 77 per cent against death, research published in the journal The Lancet suggests.
First of its kind
The findings are based on a national-level assessment of the effectiveness of the vaccine and is thought to be the first observational evaluation of its kind.
PARIS, FRANCE The largest real-world study yet of the Pfizer/BioNTech vaccine on Thursday confirmed that the jab provided more than 95 per cent protection against COVID-19, but found that the level dropped significantly when people received just one of the two prescribed doses. The authors of the research from Israel s national vaccination campaign said it showed real-world proof that the pandemic could be ended by rapid, global vaccination programs. An analysis of public health data from Israel one of the countries with the highest proportion of fully-vaccinated adults showed the vaccine was extremely effective in protecting even elderly individuals at a time when the more infectious English variant was dominant, according to the results published in the Lancet medical journal.
Moderna & Pfizer Vaccines Showing Promising Results Against COVID Variants
Moderna says early trial results show increased immunity against COVID-19 variants first found in Brazil and South Africa among people who took a booster shot or an experimental new vaccine. And a new study shows Pfizer s original vaccine has proven highly effective against the variant first spotted in the United Kingdom.
Meanwhile Moderna said Thursday it will start seeking full approval of its vaccine from the Food and Drug Administration by the end of the month. It s currently in use under an emergency authorization. Pfizer had already said it would begin trying for that full FDA approval by month s end.
2 Pfizer Covid-19 vaccine jabs give over 95% protection: Israel study
AFP file photo AFP, Paris AFP, Paris
The largest real-world study yet of the Pfizer/BioNTec vaccine today confirmed that the jab provided more than 95 percent protection against Covid-19, but found that the level dropped significantly when people received just one of the two prescribed doses.
The authors of the research from Israel s national vaccination campaign said it showed real-world proof that the pandemic could be ended by rapid, global vaccination programmes.
An analysis of public health data from Israel one of the countries with the highest proportion of fully-vaccinated adults showed the vaccine was extremely effective in protecting even elderly individuals at a time when the more infectious English variant was dominant, according to the results published in the Lancet medical journal.
Separately, the largest real-world study yet of the Pfizer/BioNTec vaccine confirmed that the shot provided more than 95% protection against COVID-19.
The authors of the research from Israel s national vaccination campaign said it showed real-world proof that the pandemic could be ended by rapid, global vaccination programs. An analysis of public health data from Israel one of the countries with the highest proportion of fully-vaccinated adults showed the vaccine was extremely effective in protecting even the elderly at a time when the more infectious English variant was dominant, according to results published in the Lancet medical journal.
During the analysis period, there were 232,268 confirmed COVID-19 infections, and nearly 95of samples tested were found to be the English B117 variant.